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Long-term eﬀ ects of depression treatment
In most cases, depression is a recurrent or chronic 
condition that aﬀ ects individuals over the course of 
their lifetime.1 The realisation that depression needs 
long-term treatment2 has not been matched by 
adequate evidence of the long-term eﬀ ects of speciﬁ c 
treatments, leaving a major gap in evidence for the 
clinical practice of psychiatry. The most commonly used 
long-term treatment is maintenance antidepressants. 
However, for most antidepressant drugs, the eﬃ  cacy 
of treatment lasting more than 1 year is unknown. 
The absence of evidence of the long-term therapeutic 
eﬀ ects of antidepressant drugs leaves uncertainty and 
invites controversy. In The Lancet Psychiatry, the Article 
by Nicola Wiles and colleagues3 brings perhaps the 
most substantial body of evidence of the long-term 
eﬀ ects of a treatment of major depressive disorder: 
a comprehensive report of the eﬀ ectiveness and 
cost-eﬀ ectiveness of adjunctive cognitive behavioural 
therapy (CBT) in a 3·5 year follow-up of the CoBalT trial.
In the CoBalT trial, 469 primary care patients with 
depressive symptoms of at least moderate severity 
despite adherence to antidepressant treatment were 
randomly allocated to be oﬀ ered a course of 12 to 
18 sessions of individual CBT or to continue their usual 
care that included antidepressants. Most participants 
had chronic and severe depression with comorbid 
anxiety disorders. Those who were oﬀ ered the adjunctive 
CBT had fewer depressive symptoms and were more 
likely to fulﬁ l criteria for response at 6 and 12 month 
follow-up.4 In the present study, Wiles and colleagues 
report the results of a 46 months follow-up. Outcomes 
were available from roughly 60% of participants. They 
showed that the beneﬁ ts of CBT were fully maintained. 
More than 3 years after the end of treatment, 
participants who were allocated to CBT continued to 
do better on several self-reported outcomes and the 
eﬀ ect sizes were similar to those at 6 and 12 months. 
Participants who received CBT scored roughly four points 
lower on the Beck Depression Inventory (mean score of 
19·2 with CBT vs 23·4 without CBT), two points lower 
on the Patient Health Questionnaire, had fewer anxiety 
symptoms, and were twice as likely to meet criteria for 
response or remission. These diﬀ erences in outcomes 
were maintained for more than 3 years whereas 
four-ﬁ fths of participants in both groups continued to 
take antidepressant drugs. An accompanying health 
economic analysis shows that add-on individual CBT 
provides exceptionally good value for money.
The CoBalT ﬁ ndings are in agreement with previous 
smaller studies5,6 that suggested that the eﬀ ects 
of CBT for depression can last for years. Although 
antidepressant drugs and brain stimulation treatments 
are eﬀ ective only as long as the treatment is continued, 
CBT provides long-term beneﬁ ts without continued 
treatment or booster sessions, which is probably because 
the participants learn skills that they continue practising 
after the treatment stops. Consequently, discontinued 
CBT might be as eﬀ ective as continued treatment with 
antidepressant medication and more eﬀ ective than 
antidepressant medication that is discontinued.7 CBT has 
been shown to improve functional outcomes, including 
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that the lasting therapeutic eﬀ ects of CBT are maintained 
even in individuals with severe, chronic, and comorbid 
depression who did not respond well to antidepressants.
In combination with previous smaller studies, the 
results of the long-term follow-up of CoBalT suggest 
that CBT should be routinely oﬀ ered to individuals 
with major depressive disorder who do not have 
satisfactory improvement with antidepressants 
alone. This conclusion leaves a quandary about the 
availability of high quality CBT in routine clinical 
setting. The fact that very few CoBalT participants 
received CBT as part of their usual care during the 
3·5 year follow-up reﬂ ects poorly on the availability 
of structured evidence-based therapies even in a 
country that invested substantially in their provision. 
Questions might be raised about whether similar 
long-term beneﬁ ts might be achieved with other types 
of psychological treatments or with less intensive 
forms of therapy delivery, such as group, self-help, 
computerised, or internet-delivered psychological 
treatments. However, no similar evidence for 
long-term eﬃ  cacy in severely aﬀ ected individuals is 
available for any less intensive treatment, and the 
one similar long-term study9 of another psychological 
therapy suggested that, even with regular booster 
sessions, interpersonal psychotherapy did not match 
the maintenance eﬀ ect of a continued antidepressant. 
Individual CBT is presently the only psychological 
treatment with robust evidence for improving 
long-term outcomes of major depressive disorder.
Notwithstanding the positive results, the CoBalT trial also 
reminds us that even a combination of antidepressants 
and individual CBT does not provide a complete solution 
for major depressive disorder.4 Years after receiving 
individual CBT and continued antidepressant treatment, 
the average CoBalT participant still scored 19 points on 
the Beck Depression Inventory, which puts them into the 
moderately depressed range. Although data for functional 
outcomes such as employment are missing, these 
symptoms probably continue to seriously aﬀ ect quality of 
life and productivity. Therefore, clinicians and researchers 
should focus on strategies to increase the eﬃ  cacy of the 
existing treatments and on developing more eﬀ ective 
treatments for major depressive disorder. 
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Mental distress and potentially modiﬁ able social factors in 
post-conﬂ ict Sri Lanka
The number of people aﬀ ected by protracted conﬂ icts 
is surging, especially in North Africa, the Middle 
East, and eastern Europe, leading to large-scale 
population displacements. Conﬂ ict-related violence 
and displacement have a direct association with 
mental health problems.1 For example, in Sri Lanka—a 
country emerging from three decades of civil conﬂ ict—
populations are showing substantial negative mental 
health consequences of conﬂ ict, such as depression, 
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